BC
BEAM icon

Bridgefront Capital’s Beam Therapeutics BEAM Stock Holding History

Bridgefront Capital’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-34,018
Closed -$811K – 522
2026
Q1 		$811K Buy
+34,018
New +$944K 0.2% 160
2024
Q3 		– Sell
-13,755
Closed -$322K – 537
2024
Q2 		$322K Buy
+13,755
New +$338K 0.13% 272

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Bridgefront Capital's BEAM Position: Q2 2026 in Review

Bridgefront Capital sold out of Beam Therapeutics (BEAM) in Q2 2026, closing a stake of 34,018 shares — an estimated $811K sold.

Bridgefront Capital first reported a position in BEAM in Q2 2024 and held it in 2 quarters. The position peaked at $811K in Q1 2026. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Bridgefront Capital reported no remaining Beam Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Bridgefront Capital sold 34,018 Beam Therapeutics shares in Q2 2026, an estimated $811K.
  • Bridgefront Capital first reported a position in Beam Therapeutics in Q2 2024 and held it in 2 quarters.
  • Bridgefront Capital's Beam Therapeutics position peaked at $811K in Q1 2026.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.